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RESEARCH ARTICLE
The relationship between affective disorders and hormonal and metabolic parameters 
in women with polycystic ovary syndrome
Polikistik over sendromlu kadınlarda afektif bozukluklar ile hormonal ve metabolik 
parametreler arasındaki ilişki
Nilgün Güdücü1, Uzay Görmüş2, Özge Başak Kayan1, Zehra Neşe Kavak3, İlkkan Dünder1
ÖZET
Amaç: Polikistik over sendromlu (PKOS) hastalarda 
afektif bozukluklar ile hormonal ve biyokimyasal paramet-
reler arasındaki ilişkiyi anlamak.
Yöntemler: PKOS tanısı almış 15 hasta, yaş ve vücut 
kitle endeksi benzer olan kontrol grubuyla (n=19) karşı-
laştırıldı.  Beck  Depresyon  Ölçeği  ve  Durumluk-Sürekli 
Anksiyete  Ölçeği  kullanılarak  anksiyete  ve  depresyon 
semptomları sorgulandı.
Bulgular:  Polikistik  over  sendromlu  hastaların  depres-
yon ve anksiyete skorları serbest testosterone seviyeleri 
ile korele idi. Anksiyete skorları HDL ve kardiyovasküler 
hastalıklar için bağımsız bir risk faktörü olarak kabul edi-
len lipoprotein-a ile koreleydi. Kontrol grubunda anksiyete 
skorları interlökin 1beta ile koreleydi.
Sonuç: Polikistik over sendromlu hastalarda androjenler 
ve afektif bozukluklar arasında bağlantı vardır. Lipopro-
tein-a ve anksiyete skorları arasındaki korelasyon afek-
tif bozukluklar ve kardiyovasküler hastalıklar arasındaki 
bağ olabilir. Polikistik over sendromlu kadınlarda afektif 
bozuklukların  patofizylojisinde  farklı  bir  mekanizma  rol 
oynayabilir.
Anahtar kelimeler: Polikistik over sendromu, testostero-
ne, anksiyete, depresyon
ABSTRACT
Objective: To understand the relationship among affec-
tive disorders and hormonal and biochemical parameters 
in women with polycystic ovary syndrome (PCOS).
Methods: Women with PCOS (n=15) were compared to 
body mass index and age matched control group (n=19). 
Beck Depression Inventory and Stait Trait Anxiety Inven-
tory were used to assess the presence of depression and 
anxiety symptoms. 
Results: Depression and anxiety scores of women with 
PCOS correlated with free testosterone levels. Their anxi-
ety scores correlated with HDL and lipoprotein-a (Lp-a), 
an independent marker for increased cardiovascular dis-
ease. In the control group anxiety score correlated with 
interleukin-1β.
Conclusion: There was a relationship between increased 
androgens and affective disorders in women with PCOS. 
The  correlation  between  Lp-a  and  anxiety  scores  may 
be the link between affective disorders and cardiovas-
cular diseases. A different mechanism may play role in 
the pathophysiology of affective disorders in women with 
PCOS. J Clin Exp Invest 2013; 4 (1): 13-19
Key words:  Polycystic  ovary  syndrome,  testosterone, 
depression, anxiety
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common 
endocrinological disorder, where the patients pres-
ent  with  chronic  oligo/anovulation,  clinical  and/
or  biochemical  hyperandrogenism  and  polycys-
tic  ovaries  on  ultrasound.1  In  women  with  PCOS 
hyperandrogenism,  insulin  resistance  (IR)  and 
obesity produce a vicious cycle and lead to other 
metabolic problems. Recently, a chronic low-grade 
inflammatory  state  is  being  proposed  as  the  un-
derlying mechanism of atherosclerosis and affec-
tive  disorders  such  as  depression  and  anxiety.2,3 
An  increased  prevalence  of  depression  was  also 
reported in patients suffering from metabolic syn-
drome (MS).4,5 Levels of inflammatory biomarkers 
were higher in MS patients with depression when 
compared to those without MS.5 Women with PCOS 
have an increased prevalence of MS and its com-
ponents. A recent study analyzing depression and Güdücü et al. Affective disorders and hormonal/metabolic parameters in polycystic ovary syndrome 14
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anxiety  in  PCOS  patients  detected  a  correlation 
between  cardiovascular  risk  factors  and  depres-
sion scores.6 Women with PCOS has augmented 
levels  of  androgens. The  embarrassment  caused 
by  clinical  manifestations  of  hyperandrogenism 
(alopecia,  hirsutism,  acne),  obesity  and  infertility 
may decrease self-esteem and may increase body 
dissatisfaction  in  women  with  PCOS.  In  addition, 
future health consequences related to PCOS may 
increase their anxiety. These features may also in-
crease the probability of weight gain by inducing so-
cial isolation and creating further opportunity to eat. 
The  metabolic  components  of  affective  disorders 
are not clear. We conducted this study in effort to 
search the relationship among cardiovascular dis-
ease risk markers, hormonal parameters and affec-
tive disorders in PCOS patients.
METHODS
This  study  was  performed  by  recruiting  patients 
from  the  Obstetrics  and  Gynecology  policlinic  of 
İstanbul Bilim University Avrupa Hospital. The study 
protocol was approved by the Institutional Review 
Board of İstanbul Bilim University. The study proto-
col was in confirmation with the ethical guidelines 
of the Declaration of Helsinki. Women with PCOS 
who gave blood for tests in the last 3 months were 
invited to participate this study. Diagnosis of PCOS 
was established according to 2003 Rotterdam ES-
HRE/ASRM  PCOS  Consensus  Workshop  Group 
Criteria,7 when at least two of the following crite-
ria  were  present:  oligo/amenorrhea  (cycles  last-
ing longer than 35 days), clinical and/or biochemi-
cal  hyperandrogenism  and  PCO  (presence  of  an 
ovary with 12 or more follicles measuring 2-9mm 
in diameter on ultrasonography). All of the subjects 
in the control group were age and body mass in-
dex (BMI) matched, most of them were students of 
medicine and hospital staff, they had a normal pel-
vic ultrasound, regular periods and no clinical and 
biochemical hyperandrogenism. Patients with sys-
temic diseases as diabetes mellitus, cardiovascular 
diseases,  hypertension,  thyroid  diseases,  chronic 
renal failure, malignancy, Cushing syndrome, con-
genital  adrenal  hyperplasia,  hyperprolactinemia 
and gastrointestinal malabsorptive diseases were 
excluded. None of the patients were on any medica-
tions for at least 3 months before the study including 
oral contraceptives, glucocorticoids, lipid-lowering, 
antiobesity, antidiabetes, antiandrogenic, antihyper-
tensive or ovulation-inducing agents. We obtained 
written informed consent from all of the participants.
All  of  the  patients  underwent  a  physical  ex-
amination and appropriate laboratory tests were 
performed. BMI was calculated as body weight in 
kilograms divided by height in metre squared (kg/
m²).  We  measured  weight,  height  and  waist  and 
hip circumferences. Waist circumference (WC) was 
obtained as the smallest circumference at the level 
of umbilicus. Hip circumference (HC) was obtained 
as the widest circumference at the level of the but-
tocks. Serum samples were obtained from all wom-
en in the early follicular phase after an overnight of 
fasting, during the 3rd-4th days of the cycle. Levels 
of fasting plasma glucose, insulin, total cholesterol, 
high-density lipoprotein (HDL), low density lipopro-
tein (LDL), triglycerides (TG), Luteinizing Hormone 
(LH), Follicle Stimulating Hormone (FSH), prolac-
tin, Thyroid Stimulating Hormone (TSH), C-reactive 
protein  (CRP),  dehydroepiandrosterone  sulfate 
(DHEAS), free testosterone, cortisol, free T4, 17-
OH  progesterone,  estradiol  (E2),  sex-hormone 
binding  globulin  (SHBG)  and  lipoprotein-a  (Lp-a) 
were measured. All of the parameters were studied 
readily except interleukin-6 (IL-6) and interleukin-1β 
(IL-1β). Centrifuged blood was stored at -80ºC and 
levels of IL-6 and IL-1β were studied later.
Free androgen index (FAI) was calculated with 
the formula FAI= total testosterone (nmol/l) x100/
SHBG (nmol/L), FAI levels ≥ 5 were indicative of 
PCOS.8 Insulin resistance was calculated by ho-
meostasis model assessment (HOMA) index with 
the  formula:  HOMA-IR=  fasting  insulin  (mU/ml)x 
fasting plasma glucose (mg/dl)/405. HOMA-IR lev-
els less than 2.75 mg/dl were considered as normal.
To assess depressive symptoms we used a 
Turkish version of 21 item Beck Depression Inven-
tory (BDI), a score ≥17 was considered as the pres-
ence of severe depressive symptoms that require 
treatment, a score <11 was considered as the ab-
sence of depressive symptoms and a score of 11-
16 was considered as the presence of mild-to-mod-
erate depressive symptoms. To measure the level 
of anxiety among patients we used a Turkish ver-
sion of State-Trait Anxiety Inventory (STAI) which 
is  composed  of  two  separate  scales,  STAI-State 
(acute) and STAI-Trait (long-standing). Each scale 
consisted of 20 statements that addressed the anxi-
ety level of the participant. A sum of scores ≥ 42 
was considered as the presence of severe anxiety, 
a score of 37-41 was considered as the presence of 
mild-moderate anxiety and a score <36 was consid-
ered as the absence of anxiety.
Statistical analysis
Statistical analyses were performed using the NCSS 
(Number Cruncher Statistical System) 2007&PASS 
(Power Analysis and Sample Size) 2008 Statistical Güdücü et al. Affective disorders and hormonal/metabolic parameters in polycystic ovary syndrome 15
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Software (Utah). Data showing normal distribution 
of parameters were compared with Student’s t-test, 
data showing non-normal distribution of parameters 
were compared with Mann Whitney U test, quali-
tative  data  were  compared  with  Chi-square  test, 
correlation of BDI , STAI-S and STAI-T with other 
parameters were measured with Spearman’s and 
Pearson correlation analysis. At a confidence inter-
val of 95% p-values <0.05 were considered statisti-
cally significant.
RESULTS
Mean age of PCOS patients was 25.4±5.3 years and 
control group was 27.2±5.5 years (p=0.346), mean 
BMI of PCOS patients was 24.0±5.4 kg/m2 and con-
trol group was 24.09±6.68 kg/m2 (p=0.985), mean 
WHR of PCOS patients was 0.82±0.07 and control 
group was 0.83±0.06 (p=0.706), mean Systolic BP 
of PCOS patients was 97.5±12.1mmHg and control 
group was 101.5±10.6 mmHg (p=0.386), mean Dia-
stolic BP of PCOS patients was 61.6±7.1 mHg and 
control group was 66.9±8.55mmHg (p=0.111). Re-
sults of BDI, STAI-S and STAI-T were presented in 
Table 1. Participants in the control group had higher 
anxiety  scores  when  compared  to  PCOS  group 
(p<0.05). Biochemical and hormonal parameters of 
women with PCOS and the control group were com-
pared in Table 2. As expected women with PCOS 
had statistically significantly higher free testoster-
one, free androgen index (FAI), LH and lower FSH 
when compared to the control group (p<0.05).
Correlation of BDI, STAI-S and STAI-T scores 
of PCOS patients with hormonal, biochemical and 
anthropometric parameters were given in Table 3. 
BDI scores were correlated with free testosterone 
and FAI positively (r=0.806, p= 0.001 and r=0.551, 
p=0.041 respectively) and with HDL negatively (r=-
0.666 and p=0.007). STAI-S scores correlated posi-
tively with free testosterone (r=0.553 and p=0.032) 
and negatively with HDL and TSH (r=-0.513, p=0.05 
and r=-0.550, p=0.034 respectively). STAI-T scores 
correlated positively with free testosterone and lipo-
protein-a (r=0.640, p=0.01 and r=0.566, p=0.035).
Correlation of BDI, STAI-S and STAI-T scores 
of the control group with hormonal, biochemical and 
anthropometric parameters were given in Table 4. 
Only STAI-T score correlated positively with IL-1β 
(r=0.468 and p=0.043).
Table 1. Comparation of Beck Depression Inventory (BDI), State Trait Anxiety Inventory-State (STAI-S) and -Trait 
(STAI-T) points of PCOS and control groups (mean ± standard deviation)
PCOS Group 
(n=15)
Control Group
(n=19) p-value
BDI 9.4±7.9 (8) 12.7±7.2 (11) a 0.321
STAI-S 31.8±10.7 40.7±10.3 0.021*
STAI-T 40.1±8.5 42.6±7.7 0.364
n (%) n (%) bp 
BDI Normal 9 (60) 9 (47.4)
Minor 4 (26.7) 4 (21.1) 0.461
Depressive 2 (13.3) 6 (31.6)
STAI-S Normal 12 (80) 7 (38.9) 0.043
Anxious 3 (20) 11 (61.1) *
STAI-T Normal 6 (40) 4 (21.1)
Minor Anxiety 4 (26.7) 5 (26.3) 0.421
Anxious 5 (33.3) 10 (52.6)
a Mann Whitney U Test, bChi-square test, *p<0.05Güdücü et al. Affective disorders and hormonal/metabolic parameters in polycystic ovary syndrome 16
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Table 2. Biochemical and hormonal parameters of the control and PCOS group [Mean±Standard Deviation (Median)]
PCOS 
(n=15)
Controls 
(n=19) p
Fasting blood glucose (mg/dl) 91.47±5.5 89.6±6.1 0.370
aIL-6 (ng/dl) 13.3±7.4 (10.4) 14.1±4.9 (12.6) 0.066
IL-1β (ng/dl) 9.1±1.8 9.4±1.8 0.691
E2 (pg/ml) 34.6±7.8 35.7±11.6 0.751
aTriglyceride(mg/dl) 63.8±32 (54) 67.2±26.4 (68) 0.455
HDL (mg/dl) 54.2±14.9 54±12.4 0.957
LDL (mg/dl) 101.3±29.3 99.8±32 0.886
aD-HEAS (ug/dl) 289.2±101.6 (296.2) 262±156 (209) 0.157
aFree Testosterone (ng/dl) 0.67±0.3 (0.6) 0.47±0.3 (0.4) 0.023*
Insulin (uU/ml) 8.9±4.9 10±4.7 0.488
aLipoprotein-a (mg/dl) 21.9±22.7 (10.7) 28.5±39.9 (9.4) 0.742
aCRP (mg/l) 1.6±3.6 (0.16) 0.99±1.2 (0.6) 0.199
FSH (mIU/ml) 5.3±1.6 6.9±2.3 0.029*
aLH (mIU/ml) 8.6±3.6 (6.8) 5.7±2.3 (4.7) 0.010*
aTSH (uIU/ml) 2±0,9 (2) 2.4±1.1 (2) 0.543
aHOMA-IR  2.4±1.52 (1.8) 2.3±1.1 (2) 0.903
aSHBG (nmol/l) 48.9±27 (36.9) 50.8±29 (38.7) 0.689
aFAI  3.7±1.9 (3.4) 2.6±2 (1.9) 0.042*
a Mann Whitney U Test, *p<0.05
Table 3. Correlation among anthropometric, hormonal and biochemical parameters and Beck Depression Inventory 
(BDI), State Trait Anxiety Inventory-State (STAI-S) and -Trait (STAI-T) scores in PCOS group
PCOS Group BDI STAI-S STAI-T
a r p r p r p
Age -0.151 0.590 0.078 0.781 0.006 0.984
Weight 0.330 0.230 -0.027 0.925 0.384 0.157
Height 0.026 0.926 0.131 0.643 0.136 0.628
BMI 0.333 0.225 -0.060 0.831 0.344 0.210
WHR 0.450 0.093 0.120a 0.670 0.258a 0.353
Fasting Blood Glucose -0.022 0.937 -0.184 0.511 -0.069 0.808
IL-6 0.147 0.601 0.166 0.553 -0.083 0.768
IL-1β -0.036 0.899 0.030 0.915 -0.073 0.796
E2 -0.127 0.651 0.017 0.953 -0.149 0.595
TGC 0.438 0.102 0.014 0.960 0.404 0.135
HDL -0.666 0.007** -0.513 0.050* -0.461 0.084
LDL 0.438 0.103 0.077 0.786 0.429 0.111
D-HEAS 0.382 0.160 0.430 0.110 0.472 0.076
F.Testosterone 0.806 0.001** 0.553 0.032* 0.640 0.010*
Insulin 0.054 0.849 0.080 0.778 0.067 0.811
Lipoprotein-a 0.465 0.094 0.258 0.374a 0.566a 0.035*
CRP 0.194 0.489 -0.074 a 0.792 -0.213a 0.446
FSH -0.106 0.707 -0.278 0.315 -0.089 0.752
LH -0.109 0.698 -0.055 0.847 0.076 0.788
TSH -0.209 0.295 -0.550 0.034* -0.456 0.087
HOMA-IR 0.146 0.603 -0.444a 0.877 -0.077a 0.784
SHBG -0.406 0.150 -0.238a 0.413 -0.177a 0.545
FAI 0.551 0.041* 0.297a 0.302 0.361a 0.205
Systolic BP  -0.306 0.334 -0.320 0.311 0.230 0.472
Diastolic BP  -0.184 0.567 -0.307 0.332 0.158 0.624
r=Spearman’s rho, a r=Pearson Correlation, *p<0.05, **p<0.01Güdücü et al. Affective disorders and hormonal/metabolic parameters in polycystic ovary syndrome 17
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Table 4. Correlation among anthropometric, hormonal and biochemical parameters and Beck Depression Inventory 
(BDI), State Trait Anxiety Inventory-State (STAI-S) and -Trait (STAI-T) scores in the control group
Control Group BDI STAI-S STAI-T
a r p r p r p
Age -0.450 0.053 -0.183 0.468 0.005 0.984
Weight -0.033 0.895 -0.323 0.191 -0.215 0.377
Height -0.019 0.938 0.410 0.091 -0.138 0.573
BMI  0.026 0.915 -0.453 0.059 -0.223 0.359
WHR -0.391 0.097 -0.158 a 0.532a -0.015a 0.953
Fasting Blood Glucose  0.175 0.473 -0.067 0.791 -0.051 0.837
IL-6 0.089 0.718 0.174 0.490 0.159 0.517
IL-1β 0.244 0.313 0.459 0.055 0.468 0.043*
E2 -0.022 0.929 0.103 0.684 0.109 0.656
TGC -0.279 0.248 -0.120 0.635 -0.207 0.394
HDL 0.041 0.868 -0.115 0.649 -0.096 0.695
LDL 0.094 0.702 -0.126 0.619 -0.013 0.958
D-HEAS 0.125 0.610 -0.102 0.688 -0.118 0.631
F.Testosterone 0.158 0.519 -0.114 0.652 0.023 0.926
Insulin 0.031 0.900 -0.070 0.782 -0.150 0.539
Lipoprotein-a 0.411 0.090 -0.199 a 0.445  0.001 a 0.998
CRP 0.310 0.197 -0.076 a 0.763 0.086 a 0.725
FSH 0.168 0.491 -0.161 0.523 -0.297 0.216
LH 0.190 0.436 -0.077 0.761 0.182 0.455
TSH 0.048 0.845 -0.282 0.258 -0.232 0.339
HOMA-IR 0.018 0.943 -0.049 a 0.848 -0.150 a 0.539
SHBG 0.019 0.937 0.013 a 0.958 0.147 a 0.548
FAI 0.024 0.929 0.246 a 0.359 0.072 a 0.790
Systolic BP 0.367 0.218 -0.220 0.470 0.095 0.757
Diastolic BP 0.355 0.234 -0.406 0.169 0.158 0.606
a r=Spearman’s rho
DISCUSSION
This study proved the presence of a relationship be-
tween affective symptoms and abnormal metabolic 
parameters  inherent  to  PCOS.  We  found  higher 
depression and anxiety scores in the control group 
when compared to women with PCOS. In contrast 
to our study most of the previous studies reported 
increased depression rates in women with PCOS.6,9-
13 One of the most interesting findings of our study 
was  the  higher  depression  scores  in  the  control 
group, but the lack of correlation between depres-
sion  scores  and  metabolic  parameters.  Although 
women with PCOS had lower depression scores, 
their scores were in correlation with the metabolic 
parameters.  In  our  study  depression  scores  of 
women with PCOS correlated positively with free 
testosterone and FAI. Some of the previous stud-
ies  rejected  the  association  between  depression 
and hirsutism scores or androgen levels,6,10,13 -15 and 
some others remained unclear.16 Another study re-
ported higher than normal free testosterone levels 
in PCOS and found correlation between depression 
scores and lower testosterone levels.17 Increased 
depression  in  PCOS  was  also  suggested  to  be 
due to the physical appearance created by hirsut-
ism and obesity.18 We did not check the contribu-
tion of Ferriman-Gallwey scores to our results, but 
we failed to detect a correlation among depression 
scores and weight or BMI of PCOS patients. We-Güdücü et al. Affective disorders and hormonal/metabolic parameters in polycystic ovary syndrome 18
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ber et al reported the relationship among increased 
androgens and depression long ago,19 in contrast 
another study linked lower free testosterone levels 
to depression.20 Even low-dose testosterone treat-
ment  was  recommended  to  relieve  symptoms  of 
depression.21 The relationship between testoster-
one and mood has not been clearly explained but 
was suggested to be due to increased sympathetic 
nerve activity in women with PCOS.22 An alternative 
explanation was through modulation of neurotrans-
mitters in the central nervous system.23
Insulin resistance is a common feature of both 
obese and lean PCOS and is considered to contrib-
ute to hyperandrogenism. Treatments improving in-
sulin sensitivity also reduced hyperandrogenism.22 
Cinar et al documented the relationship among de-
pression and IR and lipid abnormalities in women 
with PCOS.6 In our study PCOS patients with de-
pression  had  statistically  significantly  lower  HDL 
values but similar to Adali et al.14 we did not detect 
the relationship between depression and impaired 
glucose tolerance reported in previous studies.13,14 
PCOS with depression were reported to have high-
er BMI when compared to PCOS without depres-
sion.13,14 One study reported higher depression rates 
in obese PCOS when compared to obese controls.6 
In our study there was no association between BMI 
and depression scores.
We did not detect any association between de-
pression scores and inflammatory markers. Benson 
et al reported higher CRP, IL-6 and white blood cell 
count in PCOS patients with depression but the ef-
fect was found to be related by BMI.23 Increased 
depression rates were found in the presence of in-
creased IL-6 3,24 and IL-1β.24,25 Although our con-
trol group had higher anxiety scores, their scores 
were not correlated to metabolic parameters, ex-
cept IL-1β.
Female  rats  with  androgen-induced  PCOS 
showed an anxiety-like behavior, which suggested 
a role for androgens in the regulation of neurotrans-
mitters.26 Supporting the findings of this study, high-
er anxiety scores in women with PCOS were related 
to higher free testosterone levels in our study. Pre-
viously higher anxiety scores were documented in 
PCOS with higher HOMA-IR and FAI.28 BMI was 
not  associated  with  anxiety  scores,  other  studies 
reported  diverging  findings.11,14,29,30 Another inter-
esting finding was the correlation between anxiety 
scores and Lp-a and HDL. Lp-a is a well-known in-
dependent risk factor for cardiovascular diseases 
and increased levels were reported in women with 
PCOS previously.31 Future studies directed to this 
marker may provide a further link between anxiety 
and cardiovascular diseases. Metformin treatment 
was shown to improve psychological symptoms be-
sides metabolic parameters.29 Treatment of meta-
bolic problems of women with PCOS may help them 
to cope with stress.
The main limitation of our study was the small 
number of study group. Moreover our control group, 
although BMI and age matched might not be repre-
sentative of the normal population as it was com-
posed of hospital staff, students of medicine and 
nursing.  This  might  be  the  reason  for  increased 
anxiety scores in the control group.
In conclusion, our results suggested a relation-
ship  between  increased  androgens  and  affective 
disorders in women with PCOS. A different mech-
anism may play role in the pathophysiology of af-
fective disorders in women with PCOS. Lp-a may 
be a marker associated with increased anxiety in 
cardiovascular  diseases.  Further  studies  directed 
at treatment of affective disorders by treating meta-
bolic problems are warranted.
Current knowledge on the subject: There may 
be an association between affective disorders and 
metabolic and hormonal parameters.
What this study adds: Free testosterone levels 
of women with PCOS were correlated to depression 
and anxiety scores, the same correlation was not 
observed in the control group.
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